1. Home
  2. TRDA vs FUND Comparison

TRDA vs FUND Comparison

Compare TRDA & FUND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.97

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

FUND

Sprott Focus Trust Inc.

HOLD

Current Price

$9.63

Market Cap

303.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
FUND
Founded
2016
1988
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
274.5M
303.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TRDA
FUND
Price
$6.97
$9.63
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$21.00
N/A
AVG Volume (30 Days)
252.6K
17.6K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
6.64%
EPS Growth
N/A
N/A
EPS
N/A
0.93
Revenue
$25,421,000.00
N/A
Revenue This Year
$39.97
N/A
Revenue Next Year
$50.80
N/A
P/E Ratio
N/A
$10.48
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$7.39
52 Week High
$16.45
$10.47

Technical Indicators

Market Signals
Indicator
TRDA
FUND
Relative Strength Index (RSI) 45.70 35.22
Support Level $5.75 $9.31
Resistance Level $7.02 $10.07
Average True Range (ATR) 0.47 0.19
MACD 0.27 -0.07
Stochastic Oscillator 72.36 13.40

Price Performance

Historical Comparison
TRDA
FUND

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About FUND Sprott Focus Trust Inc.

Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.

Share on Social Networks: